Highlights from ASCO
June 5, 2023
Dr Claudio Cerchione summarised the educational session on the management of multiple myeloma in special patient populations, such as elderly and patients with renal failure.
From 2 June till 6 June 2023: HIGHLIGHTS FROM ASCO
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2023 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the support of:
Daily highlights
Project in the spotlight
icml lugano 2025 in depth 1
May 11, 2025
The ALLELE trial is investigating tabelecleucel to treat relapsed/refractory EBV-associated PTLD disease (R/R EBV+ PTLD) arising after a solid organ transplant (SOT) or a hematopoietic stem cell transplant (HSCT). In
eha milan 2025 in depth 1
May 11, 2025
In this video, Prof Daan Dierickx, hematologist at the University Hospitals Leuven, discusses the updated results of this trial presented during EBMT 2025.
The ALLELE trial
April 11, 2025
In this video, Prof Daan Dierickx, hematologist at the University Hospitals Leuven, discusses the updated results of this trial presented during EBMT 2025.
Quality standards
April 11, 2025
In this video, Prof Dr Ivan Van Riet discusses the recent update of the JACIE quality standards for the accreditation of cell therapy centers in Europe. These quality standards are
AML transplant or not
April 11, 2025
In this video, Prof Charles Craddock discusses how improvements in the pre- and post-transplant management of these patients can lead to better outcomes.
Conception after transplant
April 10, 2025
During EBMT 20225, Ms Iebe De Quick, nurse and oncofertility coordinator at Brussels IVF, delivered a presentation on the available options for fertility presentation in oncological patients.
OS21-07 – MDS very poor risk
April 10, 2025
During EBMT 2025, Prof Dr Xavier Poiré presented the results of an analysis performed by the EBMT chronic malignancies working party looking into the outcome of MDS patients with very
Nurse symposia
April 10, 2025
During EBMT 2025, Ms. Marijke Quaghebeur chaired an interesting series of sessions dedicated to nurses working in stem cell transplantation and cell therapy.
In-depth stories
icml lugano 2025 in depth 1
May 11, 2025
The ALLELE trial is investigating tabelecleucel to treat relapsed/refractory EBV-associated PTLD disease (R/R EBV+ PTLD) arising after a solid organ transplant (SOT) or a hematopoietic stem cell transplant (HSCT). In
eha milan 2025 in depth 1
May 11, 2025
In this video, Prof Daan Dierickx, hematologist at the University Hospitals Leuven, discusses the updated results of this trial presented during EBMT 2025.
The ALLELE trial
April 11, 2025
In this video, Prof Daan Dierickx, hematologist at the University Hospitals Leuven, discusses the updated results of this trial presented during EBMT 2025.
Quality standards
April 11, 2025
In this video, Prof Dr Ivan Van Riet discusses the recent update of the JACIE quality standards for the accreditation of cell therapy centers in Europe. These quality standards are
AML transplant or not
April 11, 2025
In this video, Prof Charles Craddock discusses how improvements in the pre- and post-transplant management of these patients can lead to better outcomes.
Conception after transplant
April 10, 2025
During EBMT 20225, Ms Iebe De Quick, nurse and oncofertility coordinator at Brussels IVF, delivered a presentation on the available options for fertility presentation in oncological patients.
OS21-07 – MDS very poor risk
April 10, 2025
During EBMT 2025, Prof Dr Xavier Poiré presented the results of an analysis performed by the EBMT chronic malignancies working party looking into the outcome of MDS patients with very
Nurse symposia
April 10, 2025
During EBMT 2025, Ms. Marijke Quaghebeur chaired an interesting series of sessions dedicated to nurses working in stem cell transplantation and cell therapy.
Poster selection
Longer survival with momelotinib than with best available therapy in ruxolitinib-pretreated myelofibrosis: results of a matching-adjusted indirect comparison
December 24, 2024
In a poster presented at the 2024 annual ASH meeting, Prof Francesca Palandri, haematologist in the IRCCS Azienda Ospedaliero at the University of Bologna (Italy), shared the results of a
Blood-derived cell-free DNA for disease monitoring in patients with multiple myeloma
December 20, 2024
In his poster presented at ASH 2024, Dr Robbe Heestermans, clinical biologist in training at the University Hospital Brussels (Brussel, Belgium), shares the results of his research into peripheral blood-based
Tagraxofusp induces a rapid restoration of normal hematopoiesis in patients with newly-diagnosed BPDCN
December 20, 2024
During ASH 2024, Prof Dr Marina Konopleva from the Albert Einstein College of Medicine (Bronx, NY, USA) presented the results of a sub analysis of a phase II study evaluating
Impact of emicizumab on mental liberation in haemophilia A patients
December 20, 2024
Prof Dr Cédric Hermans, a haematologist at Cliniques Universitaires Saint-Luc in Brussels presented data on emicizumab, a new treatment for haemophilia A.
Momelotinib for myelofibrosis with anaemia: Spanish real-world data
December 12, 2024
Dr Lucia Pérez-Lamas, a haematologist at Hospital Universitario Puerta de Hierro, Madrid, Spain, presented real-world data on momelotinib for myelofibrosis patients with anaemia, collected from 54 patients across 74 centres.
Return to work after allogeneic stem cell transplantation (SOPRALLO project)
July 17, 2024
Dr Yana Stepanishyna, a haematologist at the Institut Jules Bordet in Brussels, presents a preliminary analysis from the SOPRALLO project.
Allogeneic hematopoietic stem cell transplantation (HSCT) has significantly extended
Matching-adjusted indirect comparisons of bispecific antibodies in R/R FL
July 17, 2024
Epcoritamab (EPCOR) is a novel, subcutaneous CD3xCD20 bispecific antibody (bsAb) that has demonstrated deep and durable responses with manageable safety in patients with R/R FL following at least two systemic
Targeting the IL-4 pathway in T-ALL patients
July 17, 2024
Wouter Sleeckx, a doctoral researcher at the University of Ghent, presented his research on the therapeutic potential of targeting the IL-4 signalling pathway in a subset of T-ALL patients. His